Navigation Links
ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
Date:3/16/2009

PARIS, March 16 /PRNewswire-FirstCall/ -- ExonHit Therapeutics (Alternext: ALEHT) today reported the publication in Lancet Oncology of a study conducted by Institut Gustave Roussy, which describes the identification of a deregulated cell function in breast cancer through the analysis of alternative RNA splicing [1]. Study data demonstrate that exons are differently expressed in malignant and benign lesions, and alternative transcripts determine the molecular characteristics of breast malignancy.

"The splice variants that we have identified could be used as targets for development of targeted therapies and also for a more precise diagnostic test. A molecular diagnosis for breast cancer could improve the performance of current diagnosis methods by increasing accuracy of cytological investigations and decreasing the use of core-needle biopsy or exploratory surgery," said Fabrice Andre, M.D. Breast Cancer Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France. He added: "Patients could greatly benefit from a more precise diagnosis."

"We are very happy to report that this independent study demonstrates the clinical usefulness of our SpliceArray(TM) platform. It constitutes another example of its many possible applications," stated Dr. Loic Maurel, President of the Management Board of ExonHit Therapeutics. "We are using the same technology platform for all our blood based diagnostic projects; our internally funded diagnostic test for Alzheimer's disease (EHT Dx21) and the breast, colon and prostate cancer diagnostics developed with bioMerieux. We look forward to seeing other applications of our technology and launching the first product developed with this technology on the market."

SpliceArray(TM) biochips are ExonHit's proprietary research tools [2]. They quantify mRNA expression at the exon level. They also provide a comprehensive RNA splicing analysis across the entir
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimers Disease
2. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
3. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
4. Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
5. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
6. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
7. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
8. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
9. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
10. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
11. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Market Research Report on Global and Chinese ... and in-depth market survey on Global and ... firstly reviews the basic information of X-Ray Crystallography ... The report then explores global and China,s top ... specification, capacity, Production value, and market share etc. ...
(Date:8/29/2014)... ANGELES , Aug. 29, 2014  Chuma ... both financing alternatives and turnkey support services for ... announce that FINRA processed and approved the Company,s ... 29, 2014, CannaMed Corporation will be known as ... change was accomplished through a merger with the ...
(Date:8/29/2014)... HILL, N.C. , Aug. 29, 2014 ... Leaders (KOLs) can be the difference between a product,s ... to effectively map and stratify KOL targets – and ... build the type of strong relationships upon which successful ... research, savvy pharma companies have identified internal inconsistencies in ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Implementing a Strategic Thought Leader Management & Engagement System 2
... Biosciences announced,today, the initiation of a Phase 2 ... management of acute infectious,mononucleosis. Currently, there are no ... or any other disease caused by,the Epstein-Barr virus ... of anti-viral activity,including inhibition of viral replication of ...
... Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... ), has begun a Phase 1 clinical trial of ... R343,for the treatment of allergic asthma. R343 is the ... terms of the companies, 2005 collaboration agreement, Rigel,will receive ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
(Date:8/30/2014)... PA (PRWEB) August 30, 2014 "My ... sleep knowing that, at any moment, her fever might ... order to keep me well aware of how she ... developed the TEMP ALARM to continuously monitor a child's ... develops a fever. This ensures that prompt medical care ...
(Date:8/30/2014)... August 30, 2014 Serving contented clients ... India, Profit By Outsourcing is now offering discount ... The company gives emphasize on putting forward the best ... to clients. Their dedicated team of professionals and web ... They can handle even the critical issues of web ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's #1 ... Day discount on all SEO services. While working with ... related to internet marketing. Their dedicated team of professionals ... have a deep understanding for their specialization. This further ... since the inception, they have worked with over 5000 ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The ... mesh lawsuits ( http://www.injurybeacon.com/transvaginal-mesh/ ) filed against Boston ... sever four cases selected for one of the ... on August 18, 2014, U.S. District Judge Joseph ... Virginia disagrees with Boston Scientific’s contention that a ...
(Date:8/30/2014)... "I had a handicapped friend who could not ... inventor from Wetumpka, Ala. "In order to help her be ... I came up with a way for her to use ... for the patent-pending Deezers to allow crutches to be used ... crutches, walkers, or canes at the beach. The device reduces ...
Breaking Medicine News(10 mins):Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Federal Judge Refuses Boston Scientific Request for Separate Trials in Four Bellwether Cases, Bernstein Liebhard LLP Reports 3
... As world health leaders work vigorously to consider ... Consumer Specialty Products Association says taking simple precautions can ... something everyone should take seriously," said Chris Cathcart, CSPA ... to keep themselves and their families healthy now and ...
... A West Australian research team has made the world-first ... Liar, that leads other molecules into the nucleus of ... prostate, breast and colon cancers as well as leukemia. ... Australian Institute for Medical Research (WAIMR) led by Associate ...
... Ashley Koff R.D. helps Americans find healthier choices--BEVERLY HILLS, ... proud to announce Ashley Koff Approved (AKA), the unbiased ... several years of hearing her clients, medical colleagues, and ... recognized as a trusted source in the world of ...
... Spiderman Mulholland, one of the country,s leading forensic ... mold, is conducting investigations and working with environmental ... issues that have impacted homes and buildings in ... to date points to sulfur emissions that corrode ...
... reports show Google lobbied on the electronic medical ... contradicting the Internet giant,s earlier claims that Consumer ... false."Google,s report shows a total expenditure of $880,000 ... health-related initiatives; issues relating to online personal health ...
... system to reduce , workload, improve patient care, minimize ... Vocantas Inc., a developer of automated telephone outreach solutions, ... The Ottawa Hospital to manage patients in its Thrombosis ... in the Canadian Medical Association Journal shows that CallAssure ...
Cached Medicine News:Health News:Swine Influenza Outbreak - How to Stay Healthy 2Health News:WA discovery a key to blood cell development 2Health News:Introducing 'Ashley Koff Approved' (AKA): the Stamp of Nutrition for Optimal Health 2Health News:Forensic Expert Investigating Chinese Drywall Issue 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 2Health News:Consumer Watchdog: U.S. Senate Records Reveal Google Inc. Lobbying Campaign on Personal Medical Records Law Despite Internet Giant's Denials 3Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 2Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 3Health News:Award-winning partnership proves Vocantas CallAssure effective tool for chronic disease management 4
Provides extended cold therapy to the shoulder area for acute, chronic, or post-surgical applications. The DuraKold products can help reduce pain, edema, and speed recovery....
Provides continuous cold therapy to the knee area for acute, chronic, or post-surgical applications. Cryotherapy can reduce pain, swelling and facilitate faster rehabilitation....
... The Philadelphia® Halo™ was designed in 1988 ... applied to the patient, it greatly restricts rotation ... patient recovers, the Halo can be removed while ... ,May be used in conjunction with the ...
... and cold therapy Gel Pad. Our Gel Pad ... therapy to reduce swelling and /or hot therapy ... ,To order hot and cold therapy gel pad, ... ,Our suspenders can be added to each support ...
Medicine Products: